COL26A1

Summary

COL26A1 (collagen type XXVI alpha 1 chain, HGNC:18038) is a protein-coding gene on chromosome 7q22.1, encoding Collagen alpha-1(XXVI) chain (Q96A83).

This gene encodes a protein containing an emilin domain and two collagen stretches. This gene may be associated with aspirin-intolerant asthma. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 136227 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 85 total
• MANE Select transcript: NM_001278563

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18038
Approved symbol	COL26A1
Name	collagen type XXVI alpha 1 chain
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Aliases	Emu2, EMI6
Ensembl gene	ENSG00000160963
Ensembl biotype	protein_coding
OMIM	608927
Entrez	136227

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 retained_intron

ENST00000313669, ENST00000613091, ENST00000613501, ENST00000913311, ENST00000913312, ENST00000913313, ENST00000913314, ENST00000913315, ENST00000913316, ENST00000913317, ENST00000913318

RefSeq mRNA: 2 — MANE Select: NM_001278563 NM_001278563, NM_133457

CCDS: CCDS64739

Canonical transcript exons

ENST00000313669 — 13 exons

Exon	Start	End
ENSE00001055660	101539893	101540049
ENSE00001055689	101545338	101545490
ENSE00001055691	101543998	101544096
ENSE00001055698	101549171	101549223
ENSE00001108810	101419977	101420099
ENSE00001124206	101533082	101533143
ENSE00001124224	101447684	101447787
ENSE00001133734	101547156	101547239
ENSE00001213142	101557370	101559024
ENSE00001419296	101551108	101551143
ENSE00001432304	101553326	101553376
ENSE00002313219	101362875	101363190
ENSE00003533099	101555787	101555871

Expression profiles

Bgee: expression breadth ubiquitous, 176 present calls, max score 93.45.

FANTOM5 (CAGE): breadth broad, TPM avg 9.5878 / max 265.0888, expressed in 385 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
80198	8.3346	346
80199	0.7072	219
80201	0.2884	212
80197	0.2295	158
80200	0.0281	10

Top tissues by expression

222 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney epithelium	UBERON:0004819	93.45	silver quality
vena cava	UBERON:0004087	91.66	silver quality
left ventricle myocardium	UBERON:0006566	87.41	silver quality
cardiac muscle of right atrium	UBERON:0003379	86.49	gold quality
epithelial cell of pancreas	CL:0000083	85.88	silver quality
right frontal lobe	UBERON:0002810	85.82	gold quality
body of tongue	UBERON:0011876	85.27	silver quality
prefrontal cortex	UBERON:0000451	84.64	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	84.22	silver quality
heart right ventricle	UBERON:0002080	84.15	silver quality
pylorus	UBERON:0001166	83.80	silver quality
Brodmann (1909) area 9	UBERON:0013540	83.70	gold quality
frontal cortex	UBERON:0001870	83.60	gold quality
frontal lobe	UBERON:0016525	83.60	gold quality
cardia of stomach	UBERON:0001162	83.19	silver quality
pharyngeal mucosa	UBERON:0000355	83.00	silver quality
dorsolateral prefrontal cortex	UBERON:0009834	82.64	gold quality
tongue	UBERON:0001723	82.63	silver quality
neocortex	UBERON:0001950	82.39	gold quality
pons	UBERON:0000988	82.38	silver quality
ventral tegmental area	UBERON:0002691	82.02	silver quality
inferior vagus X ganglion	UBERON:0005363	81.67	silver quality
dorsal plus ventral thalamus	UBERON:0001897	81.61	silver quality
anterior cingulate cortex	UBERON:0009835	81.38	gold quality
lateral globus pallidus	UBERON:0002476	81.29	silver quality
trachea	UBERON:0003126	81.05	silver quality
pericardium	UBERON:0002407	80.93	silver quality
cerebral cortex	UBERON:0000956	80.84	gold quality
saphenous vein	UBERON:0007318	80.56	silver quality
cerebellar vermis	UBERON:0004720	80.31	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

52 targeting COL26A1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-1976	99.74	65.48	1127
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-135A-5P	99.36	71.85	1601
HSA-MIR-135B-5P	99.36	71.63	1613
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-4641	99.28	66.64	744
HSA-MIR-4721	99.26	66.05	818
HSA-MIR-6744-3P	99.22	64.41	972
HSA-MIR-6510-5P	99.14	66.59	1081
HSA-MIR-491-5P	99.13	65.98	1468
HSA-MIR-4757-5P	99.12	64.51	981

Literature-anchored findings (GeneRIF, showing 3)

• EMID2 may be a susceptible genetic factor for aspirin hypersensitivity among asthmatics in Korean population. (PMID:21086123)
• 13 EMID2 variants were significantly associated with the presence of nasal polyps in the overall asthma group. (PMID:22217332)
• EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening. (PMID:38195652)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Col26a1	ENSMUSG00000004415
rattus_norvegicus	Col26a1	ENSRNOG00000001422

Paralogs (37): COL9A2 (ENSG00000049089), COL23A1 (ENSG00000050767), COL11A1 (ENSG00000060718), COL17A1 (ENSG00000065618), COL5A3 (ENSG00000080573), COL4A4 (ENSG00000081052), COL16A1 (ENSG00000084636), COL9A3 (ENSG00000092758), COL20A1 (ENSG00000101203), COL1A1 (ENSG00000108821), COL9A1 (ENSG00000112280), COL7A1 (ENSG00000114270), COL21A1 (ENSG00000124749), COL5A1 (ENSG00000130635), COL4A2 (ENSG00000134871), COL2A1 (ENSG00000139219), COL6A1 (ENSG00000142156), COL6A2 (ENSG00000142173), EDA (ENSG00000158813), COL1A2 (ENSG00000164692), COL3A1 (ENSG00000168542), COL4A3 (ENSG00000169031), COL22A1 (ENSG00000169436), COL24A1 (ENSG00000171502), COL18A1 (ENSG00000182871), EMID1 (ENSG00000186998), COL4A1 (ENSG00000187498), COL4A5 (ENSG00000188153), COL25A1 (ENSG00000188517), COL27A1 (ENSG00000196739), COL13A1 (ENSG00000197467), COL4A6 (ENSG00000197565), COL11A2 (ENSG00000204248), COL5A2 (ENSG00000204262), COL15A1 (ENSG00000204291), COLQ (ENSG00000206561), COL28A1 (ENSG00000215018)

Protein

Protein identifiers

Collagen alpha-1(XXVI) chain — Q96A83 (reviewed: Q96A83)

Alternative names: Alpha-1 type XXVI collagen, EMI domain-containing protein 2, Emilin and multimerin domain-containing protein 2

All UniProt accessions (1): Q96A83

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Homotrimer or heterotrimer.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Post-translational modifications. Hydroxylated on proline residues.

Miscellaneous. May be due to a competing acceptor splice site.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96A83-1	1	yes
Q96A83-2	2

RefSeq proteins (2): NP_001265492, NP_597714 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008160	Collagen	Repeat
IPR011489	EMI_domain	Domain
IPR050392	Collagen/C1q_domain	Family

Pfam: PF01391, PF07546

UniProt features (19 total): compositionally biased region 5, disulfide bond 3, domain 3, glycosylation site 2, region of interest 2, signal peptide 1, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
7BEE	X-RAY DIFFRACTION	1.94
4AU2	X-RAY DIFFRACTION	2.3
7BFI	X-RAY DIFFRACTION	2.44
7BDU	X-RAY DIFFRACTION	2.49
4AU3	X-RAY DIFFRACTION	2.78
4BJ3	X-RAY DIFFRACTION	3.04

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96A83-F1	60.08	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 56–118, 83–89, 117–126

Glycosylation sites (2): 70, 132

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1442490	Collagen degradation
R-HSA-1650814	Collagen biosynthesis and modifying enzymes
R-HSA-8948216	Collagen chain trimerization

MSigDB gene sets: 88 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_UP, RNGTGGGC_UNKNOWN, GOCC_COLLAGEN_TRIMER, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, WANG_RESPONSE_TO_BEXAROTENE_UP, GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION, GOBP_CELL_SUBSTRATE_ADHESION, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOBP_POSITIVE_REGULATION_OF_CELL_SUBSTRATE_ADHESION, GOCC_ENDOPLASMIC_RETICULUM_LUMEN, GOCC_INTERSTITIAL_MATRIX, ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP, YOSHIMURA_MAPK8_TARGETS_UP, MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3

GO Biological Process (1): positive regulation of cell-substrate adhesion (GO:0010811)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (8): extracellular region (GO:0005576), endoplasmic reticulum lumen (GO:0005788), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), extracellular matrix (GO:0031012), collagen type XXVI trimer (GO:1990324), collagen trimer (GO:0005581), endoplasmic reticulum (GO:0005783)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Degradation of the extracellular matrix	1
Collagen formation	1
Collagen biosynthesis and modifying enzymes	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
regulation of cell-substrate adhesion	1
cell-substrate adhesion	1
positive regulation of cell adhesion	1
binding	1
cellular anatomical structure	1
endoplasmic reticulum	1
intracellular organelle lumen	1
membrane	1
cell periphery	1
external encapsulating structure	1
collagen trimer	1
collagenous component of interstitial matrix	1
extracellular protein-containing complex	1
protein-containing complex	1

Protein interactions and networks

STRING

904 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
COL26A1	SERPINH1	P29043	920
COL26A1	SVOPL	Q8N434	450
COL26A1	COL21A1	Q96P44	442
COL26A1	COL23A1	Q86Y22	438
COL26A1	ZFP90	Q8TF47	427
COL26A1	NXNL2	Q5VZ03	409
COL26A1	MCCC1	Q96RQ3	398
COL26A1	ST8SIA1	Q92185	397
COL26A1	COL16A1	Q07092	392
COL26A1	ZNF396	Q96N95	387
COL26A1	COL25A1	Q9BXS0	382
COL26A1	COL20A1	Q9P218	382
COL26A1	GLIS3	Q8NEA6	371
COL26A1	COL17A1	Q9UMD9	362
COL26A1	AGBL3	Q8NEM8	359

IntAct

4 interactions, top by confidence:

A	B	Type	Score
	VAPB	psi-mi:“MI:0914”(association)	0.500
LAIR2	PLOD3	psi-mi:“MI:0914”(association)	0.350
TBP	COL26A1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (4): COL26A1 (Affinity Capture-MS), COL26A1 (Affinity Capture-RNA), COL26A1 (Affinity Capture-MS), COL26A1 (Two-hybrid)

ESM2 similar proteins: A1XQX1, A1XQX3, A1XQY0, A1XQY3, A2ATD1, B1AKI9, D0PRN4, E9PUN2, O02695, P0C7U0, P18065, P20959, P47877, P47878, P49705, P55108, P58401, P80560, Q08DA0, Q28143, Q3UR85, Q3YEC7, Q460M5, Q5QQ56, Q5QQ57, Q5R3F8, Q63376, Q63475, Q68FM6, Q6T4P5, Q7TMB0, Q7TPB0, Q80TG9, Q80Z10, Q86Y38, Q8C8T7, Q8C985, Q8WXH2, Q91VF6, Q92932

Diamond homologs: A6H6E2, F1QC17, P59900, Q13201, Q8K482, Q91VF6, Q96A83, Q96A84, Q99K41, Q9BXX0, Q9H8L6, Q9NT22, Q9Y6C2, B2RPV6, Q5RJ80, Q8BVD7, Q91VF5, Q9BXJ2, Q9W332, Q05A80, Q6IMN6, Q8R066, Q9BXJ3, P83425, Q4ZJM7, Q5FVH0, Q8K479, Q9BXJ0, P27658, Q7Z5L3, Q8CFR0, A6NHN0, Q0II24

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

85 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	68
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2994 predictions. Top by Δscore:

Variant	Effect	Δscore
7:101363186:CGCCG:C	donor_gain	1.0000
7:101363187:GCCG:G	donor_gain	1.0000
7:101363187:GCCGG:G	donor_gain	1.0000
7:101363188:CCG:C	donor_gain	1.0000
7:101363191:G:GG	donor_gain	1.0000
7:101363191:GT:G	donor_loss	1.0000
7:101420095:GTAAG:G	donor_loss	1.0000
7:101420097:AAG:A	donor_loss	1.0000
7:101420099:GGTAA:G	donor_loss	1.0000
7:101420100:G:A	donor_loss	1.0000
7:101420101:T:G	donor_loss	1.0000
7:101447784:GAGG:G	donor_gain	1.0000
7:101447785:AGGGT:A	donor_loss	1.0000
7:101447786:GG:G	donor_gain	1.0000
7:101447787:GG:G	donor_gain	1.0000
7:101447787:GGTA:G	donor_loss	1.0000
7:101447788:GTAA:G	donor_loss	1.0000
7:101447789:T:G	donor_loss	1.0000
7:101533079:CAGAA:C	acceptor_loss	1.0000
7:101533080:A:AG	acceptor_gain	1.0000
7:101533080:A:AT	acceptor_loss	1.0000
7:101533080:AGAAT:A	acceptor_gain	1.0000
7:101533081:G:GA	acceptor_gain	1.0000
7:101533081:GA:G	acceptor_gain	1.0000
7:101533081:GAA:G	acceptor_gain	1.0000
7:101533081:GAAT:G	acceptor_gain	1.0000
7:101533081:GAATG:G	acceptor_gain	1.0000
7:101539885:T:TA	acceptor_gain	1.0000
7:101539888:CCCA:C	acceptor_loss	1.0000
7:101539889:CCAG:C	acceptor_loss	1.0000

AlphaMissense

2777 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:101420073:G:C	W85C	0.999
7:101420073:G:T	W85C	0.999
7:101447747:G:C	W115C	0.999
7:101447747:G:T	W115C	0.999
7:101555824:T:C	I373T	0.999
7:101555818:T:C	L371P	0.998
7:101555836:G:C	R377P	0.998
7:101555845:T:A	I380N	0.998
7:101555845:T:C	I380T	0.998
7:101555848:T:C	L381P	0.998
7:101420014:T:C	C66R	0.997
7:101420065:T:C	C83R	0.997
7:101555824:T:G	I373S	0.997
7:101555827:T:C	L374P	0.997
7:101555845:T:G	I380S	0.997
7:101420016:C:G	C66W	0.996
7:101420065:T:A	C83S	0.996
7:101420066:G:A	C83Y	0.996
7:101420066:G:C	C83S	0.996
7:101420071:T:A	W85R	0.996
7:101420071:T:C	W85R	0.996
7:101555833:A:T	E376V	0.996
7:101555842:T:C	L379P	0.996
7:101555851:A:T	E382V	0.996
7:101419983:G:C	W55C	0.995
7:101419983:G:T	W55C	0.995
7:101420015:G:A	C66Y	0.995
7:101420067:C:G	C83W	0.995
7:101420085:C:G	C89W	0.995
7:101447751:T:A	C117S	0.995

dbSNP variants (sampled 300 via entrez): RS1000003096 (7:101486416 A>T), RS1000004368 (7:101492141 G>T), RS1000008801 (7:101461444 G>C), RS1000013976 (7:101437024 A>G), RS1000030185 (7:101555626 T>C), RS1000063243 (7:101446859 AAAAAAG>A), RS1000067392 (7:101443288 G>A), RS1000074350 (7:101412508 G>C), RS1000083583 (7:101403519 A>C,G), RS1000087698 (7:101518811 C>T), RS1000128588 (7:101529418 G>A), RS1000134060 (7:101441897 C>A,T), RS1000134688 (7:101482116 A>G), RS1000136665 (7:101452531 C>T), RS1000139016 (7:101470246 C>G,T)

Disease associations

OMIM: gene MIM:608927 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001591_2	Response to citalopram treatment	3.000000e-08
GCST001591_6	Response to citalopram treatment	3.000000e-06
GCST005580_174	Intraocular pressure	1.000000e-08
GCST005580_188	Intraocular pressure	3.000000e-08
GCST007637_30	Diffusing capacity of carbon monoxide	1.000000e-06
GCST008925_12	Lysophosphatidylcholine levels	4.000000e-08
GCST010083_284	Hemoglobin levels	1.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004695	intraocular pressure measurement
EFO:0009369	diffusing capacity of the lung for carbon monoxide
EFO:0010224	lysophosphatidylcholine measurement
EFO:0004509	hemoglobin measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10279545	Toxicity	3	aspirin
rs17135437	Toxicity	3	citalopram	Major Depressive Disorder

PharmGKB variants

6 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs4727494	COL26A1		0.00	0
rs6949799	COL26A1		0.00	0
rs10279545	COL26A1	3	0.00	1	aspirin
rs13233066	COL26A1		0.00	0
rs17135437	COL26A1	3	0.00	1	citalopram
rs17470799	COL26A1		0.00	0

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
Valproic Acid	decreases expression, increases methylation	2
propionaldehyde	decreases expression	1
aflatoxin B2	affects methylation	1
belinostat	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	decreases methylation	1
Arsenic	affects methylation	1
Aspirin	affects response to substance	1
Carbamazepine	affects expression	1
Estradiol	increases expression	1
Lead	affects expression	1
Mercury	decreases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Thiram	increases expression	1
Triclosan	increases expression	1
Aflatoxin B1	affects methylation, increases methylation	1
Raloxifene Hydrochloride	increases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists